# Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.

*biotech · news · 2026-04-13 · The Manila Times*

## Key points

- Haisco granted AbbVie exclusive global rights to develop and commercialize pain medicines, excluding Greater China.
- The licensed compounds are at preclinical to Phase 1 stages in China and target pain-related indications.
- Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments from AbbVie.
- Haisco is also eligible for tiered royalties on future net sales of the licensed pain medicines.

**Companies:** AbbVie, Haisco Pharmaceutical Group Co., Ltd.
**Countries:** China, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/13/tmt-newswire/pr-newswire/haisco-enters-into-exclusive-license-agreement-with-abbvie-to-develop-novel-medicines-for-pain/2318791)

---

Canonical: https://newsio.io/n/5e26de8d-9393-46ed-b59d-3e627d5a5b9a/haisco-grants-abbvie-the-exclusive-rights-to-develop-manufacture-and-commerciali
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works